Summary: The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or the calcium channel blocker, azelnidipine, and to discuss the possibility of utilizing them as predictors for drug selection prior to therapy. A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. The 24-hour ambulatory blood pressure measurements (ABPM) and plasma drug concentrations were obtained on the first and at the end of each treatment period, and were analyzed using population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The population PK/PD models considering circadian variations in baseline blood pressure well described the observed plasma drug concentrations and 24-hour ABPM profiles. Pre-treatment plasma renin activity (PRA) was identified as a significant covariate on the maximum drug effect (Emax) of olmesartan, whereas azelnidpine Emax was independent of patient background characteristics investigated. No patient was found to have a high Emax to one agent who also had a high Emax to the other. In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine.
Introduction
Although the therapeutic guidelines for hypertension management have continued to evolve, the results of the treatment of hypertension still reveal a poor success rate in various nations, and the theoretical basis for a more optimized and individualized treatment strategy has been in demand. [1] [2] [3] [4] Interest has been focused on the identification of demographic, physiological or genetic factors which influence antihypertensive response.
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Pre-treatment plasma renin activity (PRA) has been proposed as one of the most promising predictors which could help guide the selection of antihypertensive therapy. 3) It has been reported that antihypertensive drugs such as angiotensin receptor blockers (ARB), [8] [9] [10] angiotensin converting enzyme (ACE) inhibitors, 11, 12) and b-blockers 13) reduce blood pressure more in hypertensive patients with a higher pre-treatment PRA. In contrast, diuretics 6, 14) and calcium channel blockers (CCB) 15) show a more antihypertensive response in patients with a low-renin state. In these studies, however, the antihypertensive agents were not administered in a crossover fashion, and therefore whether the observed average trends are also reproducible in each individual patient has not yet been clearly demonstrated considering that essential hypertension is a heterogeneous disorder. The other drawback of these studies is that the pharmacokinetic (PK) variability, which is another important factor determining antihypertensive response, [16] [17] [18] was not adequately taken into consideration. Donnelly et al. pointed out that previous stu-dies on the heterogeneity of antihypertensive response have neglected interindividual variability in the PK and consequently conflicting and, in some cases, misleading statements have been provided. 16) In this report, a two-way crossover study of the AT1-receptor selective ARB olmesartan medoxomil 19, 20) and the dihydropyridine-type CCB azelnidipine 21) was conducted in Japanese patients with mild to moderate essential hypertension, and 24-hour ambulatory blood pressure monitoring (ABPM) data and plasma drug levels were applied to covariate analyses by using a population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. 22) For analyses of 24-hour ABPM data which are subject to circadian rhythms and different sources of variability (interindividual, interoccasional, and residual variability), the population PK/PD modeling approach has been shown to be suitable because it can decompose these sources of variability in baseline. 23) Given these considerations, we investigated the factors which influence the antihypertensive response to treatment with olmesartan medoxomil or azelnidipine in essential hypertensive patients, and discussed the possibility of utilizing them as predictors for drug selection prior to therapy.
Methods

Patients
Thirty Japanese patients with mild to moderate essential hypertension, as defined by mean seated cuff blood pressure AE140/90 and Ã180/110 mmHg and 24-hour ABPM mean blood pressure AE135/80 mmHg at the end of a 4-week run-in period, were enrolled in this study. All patients gave written informed consent prior to participating in this study. The informed consent form and study protocol were approved by the local ethics committee.
Study design
This study was a single-center, randomized, openlabel, 2-way crossover study of olmesartan medoxomil and azelnidipine as a monotherapy, which comprised a 4-week run-in period and two treatment periods of 8 weeks duration with a washout period of 4 weeks between two treatments. Eligible patients entered a run-in period, during which previous antihypertensive therapy was discontinued. Patients who fulfilled the entry criteria at the end of a run-in period were randomized to receive olmesartan medoxomil or azelnidipine for 8 weeks. The initial dosage was olmesartan medoxomil 10 mg once daily or azelnidipine 8 mg once daily. For patients who did not achieve the target blood pressure at the time of 4-week visit, the study drug doses were up-titrated to olmesartan medoxomil 20 mg or azelnidipine 16 mg, respectively. After a 4-week washout, patients receiving olmesartan medoxomil switched to azelnidipine, and vice versa.
Ambulatory blood pressure monitoring: The 24-hour ABPM were recorded during the fourth week of both the run-in and washout periods, and on the first (day 1) and at the end (week 8) of each treatment period. Measurements were taken every 30 minutes using a TM-2431 } Ambulatory Blood Pressure Monitor (A&D Company).
Pharmacokinetic sampling: Blood was sampled for PK from all patients just prior to the last dose and 1, 2, 4, 8, and 24 hours after the last dose on the days corresponding to the 24-hour ABPM measurements in each treatment period. The plasma concentrations of olmesartan and azelnidipine were determined by the validated liquid chromatography tandem mass spectrometry method. The lower limit of quantification for olmesartan was 1.0 ng/mL and for azelnidipine 0.1 ng/mL, with the intra-assay precision (% coefficient of variation) at 4.9% and 14.1% and the accuracy (% bias) at -6.0% and -4.8%, respectively. Olmesartan or azelnidipine was extracted from plasma using a solid phase extraction disk plate Empore } UR (3M Bioanalytical Technologies). The chromatographic system consisted of an Agilent 1100 } series pump (Agilent Technologies) and HTC-PAL } auto sampler (CTC ANALYTICS), and an Inertsil } Ph-3 (2.1× 150 mm; GL Science Inc.) was used as the analytical column. A Quattro Premier } triple-quadrupole mass spectrometer (Waters Corporation) was used for mass spectrometric detection.
Renin-angiotensin-aldosterone-system: Supine blood samples were collected during the run-in period for the determination of the PRA, plasma renin concentration (PRC), plasma angiotensin I (Ang I) concentration, plasma angiotensin II (Ang II) concentration, plasma aldosterone concentration (PAC), and serum ACE activity. A 24-hour urine sample was collected during the run-in period to determine urinary sodium excretion (UNaV).
Preliminary analysis
For the purpose of preliminary analysis only, the ABPM data were averaged hourly for each patient and then used to calculate the mean blood pressure values over the following intervals: 24-hour period, day time (7:00-22:00), and night time (22:00-7:00). The change from baseline was calculated by subtracting the mean blood pressure at the run-in period from the corresponding value at the end of the treatment period, and the relationships between the change from baseline and covariates were confirmed using univariate regression analysis. Population pharmacokinetic/pharmacodynamic model building Nonlinear mixed-effects modeling 22) was employed to analyze the plasma drug concentrations and 24-hour ABPM measurements. A sequential approach 24) was used to develop the population PK/PD models: first, the PK models were developed and then baseline blood pressure models to describe the 24-hour ABPM profile without drug treatment were built. Lastly, the drug effect model parameters were estimated using the 24-hour ABPM data with and without treatment, conditioning on the population parameter estimates of the final baseline blood pressure model, and individual Bayesian post hoc estimates of the PK parameters of the final PK model. Before performing the analysis, the number of 24-hour ABPM data was randomly reduced to 70 points per patient, so that at least 1 measurement in an approximately 1.5-hour interval was kept. Separate population PK/PD models were developed for olmesartan medoxomil and azelnidipine and for systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Software: NONMEM software version V (double precision, level 1.1) 25) was used to conduct the population analysis. The first-order conditional estimation (FOCE) method with an interaction option was predominantly employed throughout the NONMEM analyses. All other statistical analyses, data handling, and graphing were performed using S-PLUS 7J (Insightful Corporation) and SAS version 8.2 (SAS Institute).
Population PK model: Because olmesartan medoxomil is a prodrug that is rapidly and completely de-esterified to the active metabolite olmesartan during its absorption, 26) the PK modeling was based on the plasma olmesartan concentration data. Both 1-compartment and 2-compartment open models with first-order absorption, as implemented in the NONMEM subroutines AD-VAN2/TRANS2 and ADVAN4/TRANS4 respectively, 25) were investigated. Interindividual random variability was modeled for as many PK parameters as possible, if parameter identifiability was evident. Interoccasional random variability 27) was considered in the absorptionrelated parameters, because each patient had both single dosing (day 1) and steady state (week 8) profiles available, which were assumed to represent 2 separate occasions. The interindividual variability and interoccasional variability were modeled as an exponential function as shown:
where u is the individual estimate of parameter; uT is the typical population estimate; h is the interindividual random-effect of mean 0 and variance v 2 IIV; and k is the interoccasional random-effect of mean 0 and variance v 2 IOV. The residual variability was modeled with an exponential error model as shown:
where yij and â yij represent the jth observed or predicted concentration for the ith patient, respectively, and e is the residual random-effect of mean 0 and variance s 2 . Baseline blood pressure model; Since the 24-hour ABPM measurements are subject to circadian variations, a baseline blood pressure model to describe the circadian rhythm in blood pressure over a 24-hour period was built using the data from both the run-in and washout periods (two 24-hour profiles per patient). The circadian rhythm was modeled by a cosinor analysis, which characterizes the rhythm by sums of 2 or more oscillators (cosine functions) with different periods. 28) The baseline blood pressure model for the ABPM measurements was represented as follows:
where Bsl(t) is the baseline blood pressure as a function of t (clock time); u1 is the mesor (acronym for the midline estimating statistic of rhythm, that is the rhythm-adjusted mean blood pressure over 24 hours [mmHg]); u2i are amplitudes of cosine terms; u3i are acrophases (timing of cosine maximum [hr]) of cosine terms; h1, h2i, and h3i are the interindividual random variability in the mesor, amplitudes, and acrophases, respectively; k1 is the interoccasional random variability in the mesor; and e represents the additive residual variability. The optimal number of the cosine functions, n, was selected based on the objective function values (OFVs; minus twice the log likelihood), parameter identifiability, and prior knowledge.
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Population pharmacokinetic/pharmacodynamic model: A full population PK/PD model was developed using all the ABPM data with and without drug treatment (four 24-hour profiles per patient for each drug). Three models of blood pressure change from baseline were considered. The first model assumed that the size of drug effect was related to the baseline blood pressure, which included the individual mesor as a covariate as shown:
where BP(t) is the blood pressure; E(t) is the drug effect as a fractional change in the baseline mesor. The second model was the same as the first model except that the circadian rhythm in the baseline was considered as shown:
where E(t) is the drug effect as a fractional change in the baseline blood pressure at the corresponding clock time t. The third model assumed that the size of drug effect was independent of the baseline as shown:
where E(t) is the absolute change from baseline. The drug effect, E(t), was modeled by using a linear, Emax, and sigmoid Emax model. The interindividual random variability of the drug effect model parameters was modeled exponentially. Both a direct link model and an effect com- 30) were considered for the relationship between the drug concentration and the drug effect. The effect compartment model was fitted using the subroutines ADVAN4 and ADVAN5 25) for the 1-compartment and 2-compartment PK models, respectively. Model selection was based on such criteria as the goodness-of-fit plots, estimates and standard errors of the population parameters, parameter identifiability, and OFVs.
Covariate model selection: The influence of covariates was evaluated after each structural model was developed. The covariates considered in the PK model parameters were demographic factors [age, body weight, body mass index, gender], indices of renal function [serum creatinine (SCr) and creatinine clearance (CLcr) predicted with the Cockcroft-Gault equation 31) ], and indices of hepatic function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), gamma glutamyl transferase (GGT)]. The dose was also tested as a covariate. The covariates considered in the drug effect model parameters were the PRA, PRC, Ang I, Ang II, PAC, ACE activity, and UNaV at baseline. Gender and dose were the categorical covariates, which were modeled by use of an indicator variable (0/1) as follows:
where KCOV is the covariate scale factor. Continuous covariates were modeled as an exponential function and centered at the patients' median value (medianCOV) as shown:
or modeled as a linear function of the centered covariate value as shown:
The parameter-covariate relationships were explored first by visual inspection and a linear regression. The covariates thus screened were tested individually using stepwise inclusion in the NONMEM with the use of a likelihood ratio test (pº0.05).
Model evaluation: The ability of the final PK and PK/PD models to describe the observed data was investigated via the visual predictive check. Ten thousand patients were simulated with covariates values resampled from those observed in this study for the population PK models and two hundred replicates of the original dataset were simulated for the population PK/PD models using the fixed-and random-effect parameter estimates of the final models. The key parameter estimate was evaluated using the log-likelihood profiling. 32) The resulting changes in the OFVs were plotted as a function of the selected parameter estimates and interpolated by using a cubic spline.
Results
Patient characteristics
Of the 30 hypertensive patients enrolled, there was one patient where the inclusion criteria was not fulfilled and who was therefore excluded. The remaining 29 patients were employed in the analyses. Table 1 summarizes the key demographic characteristics of the patients.
Preliminary analysis
The 24-hour mean, daytime mean, and night time mean of the ambulatory DBP and SBP and their changes from baseline are displayed in Table 2 . The results of the univariate regression of change from baseline in the 24-hour mean SBP against each covariate are shown in Figure 1 . Each bar represents the predicted influence of a single covariate on the 24-hour mean SBP change. The change from baseline in the mean blood pressure for olmesartan appeared to be largely influenced by the reninangiotensin-related factors (PRA, PRC, Ang I, Ang II, and PAC), whereas that for azelnidipine was relatively stable within the observed range of these factors. The plasma drug exposures (AUCss) for azelnidipine and olmesartan were modestly correlated with their blood pressure responses. Population pharmacokinetic/pharmacodynamic model building Population PK model: A total of 317 measurable plasma concentration data of olmesartan and 308 of azelnidipine were examined. The PK of olmesartan was best described by a 1-compartment linear model with firstorder absorption and an absorption lag-time. CLcr was identified as a significant covariate on the apparent clearance (CL/F) (DOFV＝-9.285; ** pº0.01) and was incorporated into the model as shown: where CLcr is in mL/min. A decrease in CLcr by half could result in a reduction of olmesartan CL/F of approximately 20%. The interindividual variability in CL/F fell from 28.5% in the basic model to 25.5% in the final model by incorporating CLcr as a covariate. The PK of azelnidipine was best described by use of a ; k a , absorption rate constant; NE, not estimable; NT, not tested; Q/F, intercompartmental clearance; V/F, apparent volume of distribution; V C /F, apparent volume of distribution in central compartment; V P /F, apparent volume of distribution in the peripheral compartment.
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Comparative Pharmacodynamics of Olmesartan and Azelnidipine 2-compartment linear model with first-order absorption and an absorption lag-time. The relative bioavailability (Frelative) was parameterized using the data from male patients administered 8 mg as a reference (i.e. Frelative＝1). The dose-dependent increase in Frelative was estimated to be 55.4% higher at 16 mg than at 8 mg (DOFV＝ -39.046; *** pº0.001). The gender-effect on Frelative was estimated to be 71.0% higher in females than males (DOFV＝-9.855; **pº0.01), and the interindividual variability in Frelative decreased from 38.1% to 29.1% by incorporating the gender-effect. The body weight was also statistically significant (DOFV＝-4.661; * pº0.05) as a single covariate on Frelative, but could not provide further model improvement (DOFV＝-0.648; pÀ0.05). The population parameter estimates of the final models are listed in Table 3 . Figure 2 shows the observed plasma drug concentrations for olmesartan and azelnidipine, together with the 2.5th, 50th and 97.5th percentiles calculated from a simulation based on the final population PK model. The model accurately described the observed data.
Baseline blood pressure model: Baseline blood pressure models and population PK/PD models were separately developed for SBP and DBP. Since the modeling processes and their results for both blood pressure variables were similar, only the results for SBP which showed clearer results than DBP are reported in detail below. The circadian variation in baseline blood pressure was well described by a cosinor analysis. The optimal number of cosine functions was determined to be 3. Introduction of a 4th cosine function (4-hour period) to the model could improve the OFV (DOFV＝-24.150). However, the parameter identifiability was insufficient. Introduction of the interoccasional variability in the mesor significantly improved the model (DOFV＝ -148.165), but it was later removed from the final baseline blood pressure model because the interoccasional variability in the mesor and interindividual variability in the Emax were found to be not separately estimable. The population parameter estimates of the final models are given in Table 4 .
Population PK/PD model: An Emax model well described the 24-hour ABPM profiles with and without treatment for both olmesartan and azelnidipine. A linear model and a sigmoid Emax model did not provide better fits. The three models of blood pressure change from baseline were not clearly distinguishable by the OFVs, but the model with the individual mesor as a covariate (equation 4) was slightly more stable than the other two overall. An effect compartment was needed for olmesartan, and the estimate of the elimination rate constant from the effect compartment (ke0) was sufficiently small [ke0＝0.00329 (/hr)]. As for azelnidipine, the introduction of an effect compartment could not reduce the OFV significantly (DOFV＝-0.707), suggesting that the delay between the plasma concentration profile and the drug effect time-course was not evident from the data. However, since the earlier clinical trial demonstrated that the response to azelnidipine took 4 weeks to reach its steady state, 33) the following baseline Emax model was considered for the steady state data (week 8) to test this delay:
Emax･C(t) C50＋C(t) for steady state (11) where Emax is the maximum drug effect; C50 represents the potency (drug concentration resulting in half of Emax); Ess represents the baseline change due to the delayed drug response that needs 4 weeks to reach its steady state. Incorporation of Ess as a fixed-effect significantly improved the model (DOFV＝-13.394). The dose-dependent difference in Ess was further tested but was not statistically significant. The interindividual variability could be estimated in only Emax, and those in the other drug effect parameters were not introduced due to an identifiability problem or showing no significant decrease in OFV. As a result of covariate analyses, the pre-treatment PRA was identified as a significant covariate on olmesartan Emax (DOFV＝-5.610; *pº0.05) and was incorporated into 
where PRA is in ng/mL/hr. An increase in PRA of 1 ng/mL/hr could result in an increase of olmesartan Emax by 4.56% of the mesor. The interindividual variability in Figure 3b . Its profile-likeli- %CV, standard error/parameter estimate ×100; C 50 , potency; E ss , baseline change due to the delayed drug response; EC 50 , potency for an effect compartment model; E max , maximum drug effect; IIV, interindividual random variability (v 2 IIV ); k e0 , elimination rate constant from effect compartment; mesor, rhythmadjusted mean blood pressure over 24 hours; NE, not estimable; PRA, plasma renin activity; SBP, systolic blood pressure.
hood-based 95% confidence interval was estimated as 0.721-10.2, assuming that the changes in the OFVs were x 2 -distributed with 1 degree of freedom. The effects of PRC, Ang I and Ang II were also statistically significant as single covariates on the olmesartan Emax; however, they were not added to the final model because of their high correlation with PRA. No significant covariate on the Emax was identified for azelnidpine. The population parameter estimates of the final models are listed in Table 4 . Figure 4 depicts the observed 24-hour ABPM profile, together with the 2.5th, 50th and 97.5th percentiles calculated from a simulation based on the final population PK/PD model. The majority of the observed 24-hour ABPM data fell within the boundaries of the 2.5th and 97.5th percentiles of the simulated ABPM data, indicating that the model accurately described the observed data.
Model implications
The effects of the selected covariates on the plasma drug concentration profile and the 24-hour ABPM profile at steady state (week 8) were explored using a simulation approach. Figure 5 shows the predicted time course of plasma drug concentrations and blood pressure at steady state (8 weeks) in typical patients with a single covariate altered. For example, Figure 5a depicts the typical plasma olmesartan concentration time-courses in patients with CLcr at median and the extremes of range in the present study, and Figure 5d describes the typical 24-hour ambulatory systolic blood pressure time-courses in patients with pre-treatment PRA at median and the extremes of range. These results demonstrate that pre-treatment PRA could be influential on the antihypertensive response to olmesartan, but the impacts of the covariates influencing PK parameters (i.e. CLcr for olmesartan, gender for azelnidipine) on the antihypertensive response would be considered minimal.
A scatter plot of the individual predicted Emax of olmesartan versus that of azelnidipine is shown in Figure  6a . No patient was found to have a high Emax to one agent who also had a high Emax to the other. Six representative patients who showed a pronounced responsiveness to either drug (patient ID 7, 11, 24 for azelnidipine, and ID 5, 19, 27 for olmesartan) were identified in the plot of pre-treatment PRA versus UNaV (Fig. 6b) . Based on the plasma renin-urinary sodium profile classification as defined by Laragh et al., 3, 34) 3 patients with a pronounced responsiveness to azelnidipine were classified as having a low renin profile, where the low renin profile means that the relation of PRA and UNaV is below the range established by the normotensive volunteers. The 24-hour SBP measurements and the individual predictions for 2 of the 6 representative patients with a pronounced responsiveness are shown in Figure 7 .
Discussion
The present study was designed to model the population PK/PD of both the ARB olmesartan medoxomil and the CCB azelnidipine using 24-hour ABPM data, and to identify the demographic or physiological determinants of the antihypertensive response to treatment with olmesartan medoxomil or azelnidipine in Japanese patients with mild to moderate hypertension. It was demonstrated that the pre-treatment PRA level was a significant covariate on olmesartan Emax and could be most influential in the antihypertensive response to the ARB olmesartan (Fig. 5d) . Therefore, patients with a higher pre-treatment PRA were more likely to obtain a pronounced antihypertensive response to olmesartan. As for the CCB azelnidipine, an antihypertensive response was observed in all patients, and patient background characteristics investigated, including pre-treatment PRA, were not identified as a clinically significant covariate of the azelnidipine Emax. Resnick et al., however, have reported a negative correlation between the extent of blood pressure reduction after nifedipine administration and pre-treatment PRA. 15) One reason for this disagreement could be the difference in the distribution of pre-treatment PRA between these studies. It was reported that salt intake was high in the Japanese population and low-renin hyperten- Fig. 4 . Visual predictive check of the pharmacokinetic/pharmacodynamic models of olmesartan and azelnidipine for 24-hour ambulatory systolic blood pressure at baseline, after single dosing (day 1), and at steady state (week 8) The datapoints are the observed blood pressure measurements, and lines are the 2.5th, 50th (bold) and 97.5th percentiles of the simulated blood pressure data.
sion was common among Asians. [35] [36] [37] The Japanese patients in the current study exhibited pre-treatment PRA values which were relatively low and were categorized as having a normal or low renin profile in the classification of hypertensive patients defined by Laragh et al. 3, 34) ( Fig. 6b) . Based on the hypothesis contrasting renin activity-dependent and volume-dependent forms of hypertension, 3) we hypothesized that UNaV was also a likely predictor of responsiveness to olmesartan medoxomil or azelnidipine. However, this study could not detect its clinically significant effect for both drugs. It must be noted that this study involved a relatively small number of patients and type II error in covariate selection cannot be excluded. The results need to be further confirmed by a larger sample.
The major strength of the current study was that it was designed as a crossover trial; consequently, responsiveness to olmesartan and azelnidipine could be compared within individual patients. Interestingly, it was found that there was no patient with a pronounced responsiveness to one drug who associated with a pronounced responsiveness to the other. It was also found that the 3 representative patients with a pronounced responsiveness to azelnidipine were classified as low renin patients 3, 34) ( Fig. 6b) . Considering that plasma renin levels change in response to changes in dietary salt to sustain blood pressure, 3, 34, 36) it is reasonable that the forms of hypertension, renin activity-dependent or volumedependent, are determined by the statuses of both renin activity and UNaV. Although UNaV was not selected as a significant covariate on drug effect in the present study, this finding indicates a possibility that UNaV, in combination with pre-treatment PRA, may be a predictor of responsiveness to azelnidipine.
The population PK analyses indicated that CLcr was identified as a significant covariate on olmesartan CL/F and a decrease in CLcr by half could result in a reduction of CLCL/F of approximately 20%. These results were similar to those previously reported. 38) As for azelnidipine, a gender-related difference in relative bioavailability was indicated, and this could not be explained by body weight. The presence of a gender-difference in bioavailability, higher in females than males, was suggested in some drugs, 39) including the dihydropyridine-type CCB amlodipine. 40) These covariates were considered less important from the point of view of antihypertensive response ( Fig. 5e and 5f ). It is not surprising because if a dose of olmesartan medoxomil 20 mg or azelnidipine 16 mg were administered once daily, the predicted effect site drug concentrations at steady state were much higher than the estimated (E)C50 for olmesartan and azelnidipine. In the preliminary analysis, azelnidipine showed a more pronounced decrease of mean blood pressure in females than in males (Fig. 1) . Most of the observed difference between genders could be explained by the difference in the baseline blood pressure (data not shown), which was compatible with our model implications. However, it remains to be elucidated because the number of female patients enrolled was limited.
The population PK/PD analyses demonstrated that the drug effect of olmesartan at steady state was maintained constantly throughout the dosing intervals, which was well described by an effect compartment model with a small ke0 parameter estimate displaying a pronounced hysteresis. This result may partly reflect the slow dissociation kinetics from Ang II receptor, the so-called insurmountable blockade, reported for olmesartan. 19, 20) It should be noted that ke0, and in consequence EC50, could not be precisely estimated from the data and the coefficient of variation (SE/estimate ×100%) of these parameter estimates were 240% and 264%, respectively (Table 4) , probably because the 24-hour ABPM profiles were obtained at day 1 and week 8 only. However, equilibrium half-life based on the estimated ke0 was 8.8 days (i.e. approximately 4 weeks to 90% of equilibrium), which was comparable with the previously reported time to maximum antihypertensive response to olmesartan medoxomil. 41) As for azelnidipine, it was reported that its antihypertensive response took 4 weeks to reach its steady state. 33) However, in the current study the introduction of an effect compartment could not improve the model. Instead, the baseline blood pressure reduction term, Ess, was significant, indicating that along with the immediate depressor effect, a long-delayed response which could not be explained from the direct link model might exist. The dose-dependent difference in Ess was anticipated but was not statistically significant, possibly due to the dose titration design. The CCB lowers blood pressure not only by reducing the intracellular calcium levels but also by its natriuretic effect, 3, 42) which might contribute to the observed phenomenon. Another possibility is the paucity of the PK samplings, especially around its time to maximum concentration (¿2.2 hour 43) ). They might not have been sufficient to sensitively detect the putative hysteresis due to the high lipophilicity characteristics of azelnidipine. 21, 33) In conclusion, the present study shows PK/PD relationships of the ARB olmesartan medoxomil and the CCB azelnidipine in Japanese hypertensive patients using 24-hour ABPM data and gives important clinical implications for the predictive performance of pre-treatment PRA for antihypertensive response to these agents through the covariate analyses. Our findings further support the concept regarding classification of hypertension contrasting renin activity-dependent and volume-dependent forms, and help physicians to optimize treatment, especially in the choice of an ARB or CCB.
